| Prev Close | 8.15 |
| Day Low/High | 7.41 / 8.24 |
| 52 Wk Low/High | 2.23 / 10.71 |
AVEO Pharmaceuticals, Inc. (AVEO)
8.18
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 28.81B |
| Market Cap | 234.80M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Biotech Names Flexing Their Muscles
There's action in Global Blood Therapeutics and Antares Pharma.
How I've Prepared for Hurricane Irma -- and a Market Pullback
As a Miami resident, I've learned the value of hurricane preparation and the 'Jensen Rules'.
How I'm Prepared for Irma -- and a Pullback
As a Florida resident, I've learned the value of preparation and the 'Jensen Rules'.
When Eyeing Small Biotechs, Partnerships Are Huge
Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.
Playing Biotechs with the House's Money
Here's how to lock in gains on risky small-cap biotechnology stocks.
A Few Bright Spots Liven Up a Slow Week
I'm happy to once again be sitting in for Doug Kass today. It's been a remarkably boring week, with the major indices all trading in a narrow range. It feels like investors are unsure of stocks' next direction following first-quarter earnings season...
Jobs Report Aftermath
The market sold off in morning trading, despite a better-than-expected jobs report that showed new job creation of 295,000 for February and saw the unemployment rate falling again, to 5.5%. Wage growth is still not benefiting from stronger job growt...
Rare Good News for Mortgage Servicers
The market is clawing its way back to even. Oil is holding gains, and this is translating into solid gains within the E&P space today so far. This is also helping Chicago Bridge & Iron (CBI) recover some of its losses from announcement of another de...
Slim Pickings in Latest 13F Filings
Many value investors are making more concentrated bets.
Shotgun Investing in Biotech
Two speculative plays are worthy of consideration.
Another Gem for the Biotech Basket
Amid the basket's impressive performance, I'm adding Minerva.
Building a Biotech Basket
Borrowing a page from a master investor's playbook.
5 Dumbest Things on Wall Street
Scotts Miracle-No!, Synta's Sorrow and Google's Porn Problem highlight Gregg Greenberg's 5 Dumbest list this week.
Biotech's Next Big Thing: Aveo
TheStreet Sr. Columnist Adam Feuerstein says FDA reviews for cancer drugs from Aveo and Delcath are the next big thing in biotech.
Shake the Bushes
I'm looking for the hot themes or groups of 2013.
Put These Flyers Under Your Tree
These stocks may be speculative, but they sport solid sales-growth estimates -- and insiders are buying.
Walking Away From the Cliff
Some traders are shutting down for the year rather than trying to game the fiscal cliff.
Next Big Thing in Biotech: Cancer Drug Stocks
Senior columnist Adam Feuerstein explains why cancer drug stocks are the next big thing in biotech.
